Your fast, high-signal look at everything that moved biotech, medtech, and pharma today. The BioMed Nexus Daily Update delivers the most important regulatory moves, trial readouts, deals, and industry developments in one concise, easy-to-scan report. Updated every weekday morning.
Johnson & Johnson’s $3.05B Halda acquisition secures RiPTAC platform; FDA approves first interchangeable Perjeta biosimilar; Nuvalent’s ALK inhibitor delivers pivotal durability; NIH grant terminations disrupt
FDA’s “plausible mechanism” pathway transforms ultra-rare therapeutics; Siemens dramatically reduces Healthineers stake in €33.5B restructuring; gene editing platforms consolidate as capital rotates toward tools and
FDA unveils “plausible mechanism” approval route for ultra-rare therapies; gene editing biotechs restructure amid capital constraints; medtech delivers strong quarters; EU AI regulations tighten device
Richard Pazdur’s CDER appointment signals regulatory evolution; China’s biotech resurgence opens cross-border opportunities; medtech financing hits $26.6B as capital markets normalize The life sciences sector
Trump administration reprices obesity drugs at 75% discount; FDA reverses two decades of HRT warnings; Intellia patient death triggers Cas9 safety debate; and Trodelvy stumbles
A transformative week brings Amgen’s landmark cardiovascular prevention data, Medicaid’s global pricing pivot, fierce obesity M&A competition, and expanding neuroscience approvals—while AI regulation and capital
Trump administration brokers obesity drug pricing pact with Novo and Lilly; FDA approves daratumumab for earlier-line myeloma; geopolitical tensions ease for Illumina while BD navigates
Market signals diverge as Charles River raises guidance while Bio-Techne misses; Eli Lilly’s expected weight-loss drug price cuts and medtech resilience add complexity to sector
November 5, 2025 Tuesday delivered a stark reminder of biotech’s unforgiving nature as Sarepta Therapeutics collapsed 40% following a devastating Duchenne muscular dystrophy confirmatory trial
Biotech opened the week navigating extreme regulatory volatility and clinical performance divergence. uniQure suffered a devastating 49% share collapse after the FDA reversed course on
